Member Info for researcher1

Darren/wynd - cute squabbling about a few pence? Get a room! Exchange pillow talk about the move to £1.50 in the Spring, and £4 in the autumn...

ha ha - nice one Phantom. A few blaggers trying to lower the price a tad. Not going to work.

CellSearch is the usual whipping boy - it's more expensive, less accurate, and importantly cannot provide living CTCs for analysis. The fact it takes the same amount of time is therefore not an especially significant fact.

there is good volume every day wynd - hence the tight spreads

another excellent insight into the edge Parsortix has over its closest competitors - the big news is yet to come, however, so it is important that even at this level to accumulate shares - it will be much more expensive in a few months

Indeed. Also the UK clinic opening....

thanks for posting - nice to see AN being thanked at the end - one of the reasons revenue has been slight so far is due to the company policy of encouraging research use by providing P. machines for free, or cheaply. No wonder - the publicity is excellent....

I certainly indulged at 107p

yes, I've experienced it too - normally just before strong buying action, but who knows....

All my top slice (50%) is going back in today and tomorrow...

whilst Fevertree is right to be cautious about the timing of a Nasdaq listing, the difference with Angle is that it is very reasonably priced at the moment, and the revenue opportunity post-FDA will be clear to major industry players. AN is highly unlikely to sell the company below £4, and he can choose his moment to list in the US, if, as miavoce says, a direct offer does not come in first.

Please let this stay quiet for a few days, as I need to move some profits into a S&S ISA. By April (hoping FDA comes later that month) that will be 4 years of allowance, all in AGL. GLA.

I agree with Aquae - although as SBTX rises toward £1 later this year, OPTI will start to look ridiculously cheap, as its SBTX holding will be worth its entire MCAP!

I sense it will 'hang out' around £1, waiting for the FDA...

it is a great endorsement - but not really necessary given the peer reviews and the increasingly higher valuations emerging. I confess that these giddy January heights have taken me by (pleasant) surprise. £1 now appears likely in February - and then we have news coming...

you use the word 'potential' twice Shure, which is highly symptomatic of an EDEN shareholder! - let's hope this year we see some fulfilment...

spot on Dibs. I'm going to add on dips until £1. News of the first clinic soon...

ha ha - perhaps cromwell IS TW himself!

I've been investing (and trading) for 10 years now, but have never felt a share in such a good position as Angle is at the moment - way undervalued for its potential at this price - comparable shares at this juncture, awaiting trial results or FDA approval (e.g. Immupharma) have been high on fumes and then collapsed on indifferent news. Angle's SP is only in its low comfort zone, with stacks of incontrovertible peer research stacked behind its FDA submission. There will be little dips through to April, but I've decided just to keep buying, and buying....

agreed Aquae, elrico has been a charismatic voice of reason. TW owes him big time. Cromwell, which ones did you take up? - I can see he has had a much better 6 months, so why he still bothers with the old dogs, who knows....